Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma

Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2...

Related Keywords

Boston ,Massachusetts ,United States ,American ,Nathan Mellor ,Ingok Mellinghoff ,Susan Pandya ,Ingo Mellinghoff ,Prnewswire Servier ,Brock Greene ,Memorial Sloan Kettering Cancer Center ,Servier Pharmaceuticals ,European Union ,Department Of Neurology ,Servier Group ,Us Food Drug Administration ,Clinical Development ,New England Journal ,American Society ,Clinical Oncology ,Memorial Sloan Kettering Cancer ,Vice President Clinical Development ,Cancer Metabolism Global Development Oncology ,Drug Administration ,New Drug Application ,Central Nervous System ,